The agenda includes:
Preparation of a position on the assessment of the legitimacy of qualifying the health care service “Test performed in connection with an increase in the incidence of upper respiratory tract infections of viral aetiology: antigen test for Sars CoV-2 / influenza A+B / RSV” as a guaranteed benefit.
Preparation of positions on the evaluation of drugs:
- Darzalex (daratumumab) under a drug programme “Treatment of patients with newly diagnosed systemic light chain amyloidosis (AL)”,
- Fostex Nexthaler (beclometasone dipropionaate anhydricus + formoterol fumarat dihydricus) for the indications: chronic obstructive pulmonary disease; asthma.
Preparation of a position on the legitimacy of granting reimbursement approval for the medicinal product: Reducto spezial (potassium dihydrogen phosphate, sodium monohydrogen phosphate dihydrate) for the indication: hypophosphatemic rickets.
Information on the previous agenda can be found HERE